How much atrial fibrillation is too much? The net clinical benefit of anticoagulation therapy in atrial fibrillation patients with an intermediate CHA2DS2-VASc Score

Rebekah Stovall  
*James Madison University*

Ashley Carter  
*James Madison University*

Lynsey Deudne  
*James Madison University*

Follow this and additional works at: [http://commons.lib.jmu.edu/pacapstones](http://commons.lib.jmu.edu/pacapstones)

Part of the [Medicine and Health Sciences Commons](http://commons.lib.jmu.edu/polscih/22).

**Recommended Citation**

Carter A, Deudne L, Stovall R. How much atrial fibrillation is too much? The net clinical benefit of anticoagulation therapy in atrial fibrillation patients with an intermediate CHA2DS2-VASc score. JMU Scholarly Commons Physician Assistant Capstones.  
How Much Atrial Fibrillation Is Too Much?  
The Net Clinical Benefit of Oral Anticoagulation Therapy in Atrial Fibrillation Patients With an Intermediate CHA2DS2-VASc Score  
Ashley Carter, PA-S, Lynsey Deunde, PA-S, Rebekah Stovall, PA-S  
James Madison University, Harrisonburg, VA

INTRODUCTION

- Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia, affecting 33.5 million people worldwide.
- Arterial thromboembolism, particularly ischemic stroke (IS), is a significant complication of AF.
- The most widely recommended tool used to evaluate AF patient’s risk of IS is the CHA2DS2-VASc score.
- It assigns a numerical value to pre-determined IS risk factors and allows an overall estimation of the patient’s risk.
- Various organizations provide different recommendations for oral anticoagulation (OAC) therapy, making it difficult for providers to develop treatment plans for this patient population (see Table 1).

OBJECTIVES

The purpose of this review is to evaluate the net clinical benefit (NCB) when comparing IS risk to that of hemorrhagic complications when prescribing OAC therapy to patients who have at least 1 non-gender (NGR) risk factor for IS or is an intermediate CHA2DS2-VASc score.

METHODS

- A systematic review and meta-analysis were performed to identify studies and determine the net clinical benefit of oral anticoagulation therapy in patients with atrial fibrillation.
- The eligibility criteria for the studies included in the meta-analysis were as follows:
  - Patients with atrial fibrillation
  - CHA2DS2-VASc score of 1 to 2
  - Antithrombotic therapy was prescribed
  - Study design: prospective or retrospective cohort studies

RESULTS

- **Study 1**
  - **Objective:** To determine the prevalence of a single NGR risk factor increases the annual rate of IS in Taiwanese AF patients aged 20 years and older.
  - **Study Design:** Retrospective cohort using data from the National Health Insurance Research Database (NHIRD) regarding AF patients. They were assigned a CHA2DS2-VASc score based on their risk factors and outcome of IS was evaluated.
  - **Results:** The average annual IS rate for males with a CHA2DS2-VASc score of 1 was 2.75% and for females with a CHA2DS2-VASc of 2 was 2.55%.
  - **Study Critique:** It is the first population based investigation addressing our clinical question setting the stage for research to come. However it could be undermining the annual stroke risk due to inclusion of patients who could have been prescribed antithrombotic therapy 90 days after the diagnosis of AF.

- **Study 2**
  - **Objective:** To measure whether a single NGR CHA2DS2-VASc risk factor confers a significant risk of IS and if the use of OAC can reduce IS risk with minimal hemorrhagic complications.
  - **Study Design:** Retrospective community cohort investigating adverse outcomes of OAC use in nonvalvular AF patients with just one NGR risk factor in accordance with CHA2DS2-VASc risk assessment. Adverse outcomes included rates of IS, intracranial hemorrhage, major extracranial bleeding, and myocardial infarction. Net clinical benefit was calculated using 2 methodologies: Singer et al and Connolly et al formula.
  - **Results:** A positive net clinical benefit was measured in favor of vitamin K antagonists when comparing the benefit of IS reduction against the increased risk of ICH in patients with 1 NGR risk factor and nonvalvular AF. This was consistent across both the Singer and Connolly methodologies.
  - **Critique:** Real world registry data from a large cohort of consecutive patients recruited and data is complementary to data reported in randomized clinical trials. However, patients are at risk for changes in treatment during follow-up which was impossible to make adjustments for in a multivariable analysis.

- **Study 3**
  - **Objective:** To reduce uncertainty about OAC therapy in patients with a CHA2DS2-VASc score of 1 by comparing annual IS rates in AF patients to pre-determined OAC therapy thresholds.
  - **Study Design:** Systematic review and meta-analysis
  - **Results:** Patients with a CHA2DS2-VASc score of 0 do not meet the treatment threshold for OAC therapy. Patients with a CHA2DS2-VASc score of 1 meet the treatment threshold for novel OAC therapy but not warfarin. Patients with a CHA2DS2-VASc score of 2 meet the treatment threshold for both novel OAC and warfarin.
  - **Study Critique:** Weaknesses of this meta-analysis include wide confidence intervals, significant heterogeneity, several types of bias, and a lack of discussion regarding the quality of the included studies. Strengths of the study include its recent publication date, its large population size, and the variety of countries represented by the data.

CONCLUSIONS

Based on our review of the current literature, we found that the presence of even 1 NGR risk factor significantly increases a patient’s risk of IS. Therefore, we agree with the European Society of Cardiology (ESC) and the National Institute for Health and Care Excellence (NICE) guidelines that support considering anticoagulation therapy in AF patients with 1 NGR risk factor, and we suggest that the American College of Cardiology, American Heart Association, and the Heart Rhythm Society (ACC/AHA/HRS) guidelines follow suit.

ACKNOWLEDGEMENTS

We would like to thank Dr. Erika Kancler, Ms. Carolyn Schubert, and the James Madison University Graduate School and Physician Assistant Program for their assistance and contributions to our research.

REFERENCES

   http://eurheartj.oxfordjournals.org/content/37/30/2893. doi:10.1093/eurheartj/ehw310